Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

BACKGROUND: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression is unknown. METHODS: A retrospective, real‐world analysis was performed on the outcomes of 377 patients with resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez‐Larrán, Alberto, Garrote, Marta, Ferrer‐Marín, Francisca, Pérez‐Encinas, Manuel, Mata‐Vazquez, M. Isabel, Bellosillo, Beatriz, Arellano‐Rodrigo, Eduardo, Gómez, Montse, García, Regina, García‐Gutiérrez, Valentín, Gasior, Mercedes, Cuevas, Beatriz, Angona, Anna, Gómez‐Casares, María Teresa, Martínez, Clara M., Magro, Elena, Ayala, Rosa, del Orbe‐Barreto, Rafael, Pérez‐López, Raúl, Fox, Maria Laura, Raya, José‐María, Guerrero, Lucía, García‐Hernández, Carmen, Caballero, Gonzalo, Murillo, Ilda, Xicoy, Blanca, Ramírez, M. José, Carreño‐Tarragona, Gonzalo, Hernández‐Boluda, Juan Carlos, Pereira, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324831/
https://www.ncbi.nlm.nih.gov/pubmed/35417564
http://dx.doi.org/10.1002/cncr.34195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324831/
https://www.ncbi.nlm.nih.gov/pubmed/35417564
http://dx.doi.org/10.1002/cncr.34195

Ejemplares similares